Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

Inclusion Criteria: * Healthy adult as determined by medical history, physical examination, laboratory test, and clinical judgment of the investigator. * Males and females aged 20-40 years. * Provides signed informed consent form after received a detailed explanation of the study protocol prior to any study procedures. Exclusion Criteria: * Body Mass Index (BMI) 30 kg/m2 and above. * Has a history of a A/H5N1 influenza virus infection and subjects had received other A/H5N1 influenza vaccine. * Has a history of allergic reaction by food and medicine including vaccine, and acute fever illness (greater than 39.0C) within 2 days of vaccination. * Has a history of Guillain-Barre syndrome or acute disseminated encephalomyelitis (ADEM). * Has severe allergic diseases. * Has asthma. * Has a history of convulsions. * Has a history of any serious disease. * Known impairment of imune function. * Known rheumatism and autoimmune disease. * Receipt of medicines that would affect evaluation of immunogenicity. * Receipt of any live virus vaccination or receipt of any inactivated vaccine/toxoid prior to enrollment. * Blood donation prior to enrollment. * Receipt of another investigation agent prior to enrollment. * History of alcohol or drug abuse. * Females who are pregnant or potentially childbearing or are breastfeeding. * Ineligible subject based on the judgement of the investigator.